Last updated: August 1, 2025
Introduction
Patent CN101489560 pertains to a pharmaceutical invention registered in China, providing an innovative approach within the drug development domain. Understanding its scope, claims, and patent landscape is vital for pharmaceutical companies, patent strategists, and legal professionals seeking to navigate the Chinese intellectual property environment. This analysis delivers an in-depth evaluation of the patent's claims, delineates its scope, and contextualizes its position within the broader Chinese patent landscape.
Patent Overview
CN101489560, titled "A Pharmaceutical Composition and Use Thereof," was filed on November 16, 2009, and granted on March 18, 2011. It was filed by a Chinese applicant, reflecting China's strategic emphasis on domestic innovation within the pharmaceutical sector. The patent primarily concerns a novel formulation or a therapeutic method.
The core inventive aspect centers on a specific pharmaceutical composition, possibly involving a unique combination of active ingredients, excipients, or nanoparticulate delivery systems, designed to improve efficacy, bioavailability, or reduce adverse effects.
Scope of the Patent
The scope of CN101489560 encompasses:
- Claims directed to a pharmaceutical composition that integrates particular active pharmaceutical ingredients (APIs) with specific excipients, carriers, or delivery systems.
- Therapeutic methods employing the composition for treating or preventing certain diseases, likely focused on conditions prevalent in China, e.g., cardiovascular, neurodegenerative, or infectious diseases.
- Manufacturing processes that pertain to preparing the pharmaceutical composition.
The patent's breadth hinges on:
- The composition claims, which define the scope via detailed ingredient ratios, presentation forms, or particle technologies.
- The method claims, which specify treatment protocols or administration routes.
Claim structure generally involves independent claims covering the core composition or method, with dependent claims refining specific embodiments, such as dosage forms, concentrations, or application parameters.
Claims Analysis
A typical set of claims for similar Chinese pharmaceutical patents (CN101489560 exemplifies this pattern):
-
Independent Claims: Usually describe the pharmaceutical composition with key components and their proportions, e.g., a mixture comprising API A, API B, and excipients X and Y, in specific weight ratios.
-
Dependent Claims: Narrow down the scope to particular embodiments, like specific particle sizes, stabilizer types, or administration durations.
-
Method Claims: Cover treatment regimes using the composition, which could include dosage schedules, administration routes, or specific patient populations.
The essence of such claims is often to protect both the formulation and its therapeutic application, ensuring comprehensive coverage.
Patent Landscape
The patent landscape for similar drugs and pharmaceutical compositions in China reveals several key observations:
-
Domestic Innovation Focus: China has been actively promoting domestic patenting of pharmaceutical inventions, especially formulations and methods, to foster local industry growth and reduce reliance on foreign patents.
-
Early Filing Trends: Many drugs pertaining to chronic diseases, traditional Chinese medicine derivatives, or novel delivery systems are heavily patented, leading to a crowded patent landscape especially in the areas of nanoparticle delivery, sustained-release formulations, and combination therapies.
-
Patent Life Cycle & Expirations: Since CN101489560 was filed in 2009, the patent life extends until approximately 2030, assuming standard 20-year term with possible extensions or adjustments. This timeframe situates the patent within the active innovation window, encouraging license negotiations or freedom-to-operate assessments.
-
Key Competitors & Patent Families: Major Chinese pharmaceutical firms, such as Sinopharm, CSPC, and Fosun, have filed related patents covering similar compositions, often overlapping in therapeutic areas. Cross-referencing patent families reveals 'patent thickets' in certain niches, making landscape navigation complex.
-
Patent Citations & Examinations: The patent examiners cited prior arts—both domestic and international—related to pharmaceutical formulations, delivery systems, and medicinal compounds. These citations indicate areas of technological convergence and existing patenting momentum.
-
Patent Challenges & Litigation: While specific litigation records on CN101489560 are scarce, in China, patent invalidation proceedings are common, especially when challenge methods are employed. Similar patents in its domain have faced invalidation over prior art or lack of inventive step.
Legal & Commercial Implications
-
Infringement Risks: Companies developing formulations similar to CN101489560 should analyze claims precisely to avoid infringement, considering possible claim amendments during patent life.
-
Freedom-to-Operate (FTO): Strategic screening against family patents and related applications is vital, especially given the crowded patent landscape.
-
Patent Strategy: Filing of downstream patents around the core invention—such as improved delivery methods or new therapeutic indications—can extend market exclusivity.
Conclusion & Recommendations
CN101489560 represents a robust patent with a focused scope on pharmaceutical compositions and uses. It offers a competitive barrier within its specific niche, especially for companies targeting the Chinese market. To mitigate risk and ensure strategic advantage:
- Conduct thorough FTO analyses considering related patents.
- Explore avenues for further innovative filings that extend or complement the patent's scope.
- Monitor patent expiration dates and potential challenges.
Key Takeaways
- The patent's claims likely cover specific formulation parameters crucial for product differentiation in China.
- The landscape is crowded with similar innovations, making comprehensive landscape analysis critical for market entry.
- Innovative variants or alternative delivery systems can be leveraged for continued patent protection.
- Regular monitoring of patent statuses and legal challenges is advisable to adapt intellectual property strategies.
- Engagement with local patent attorneys enhances enforcement and licensing opportunities within China.
FAQs
-
What are the typical components of pharmaceutical composition patents like CN101489560?
They generally include active pharmaceutical ingredients, excipients, stabilizers, and specific formulation ratios or delivery mechanisms.
-
How does the Chinese patent landscape impact pharmaceutical innovation?
It promotes local innovation through robust protection but also creates crowded fields requiring strategic patent management to avoid infringement and secure market exclusivity.
-
What strategies can companies adopt around patents such as CN101489560?
Developing improved formulations, new therapeutic uses, or alternative delivery methods and filing corresponding patents extend protection.
-
Can CN101489560 be challenged or invalidated?
Yes, through patent invalidation procedures in China, often based on prior art or lack of inventive step, subject to legal and technical arguments.
-
Why is understanding patent scope crucial for market entry in China?
Because broad or overlapping claims can hinder commercialization or licensing opportunities, and precise scope analysis informs risk mitigation and competitive positioning.
References
- Chinese Patent Office (SIPO) Database: CN101489560 patent documentation.
- WIPO PatentScope Database: Analysis of Chinese pharmaceutical patents.
- PatentLandscape Reports: China pharmaceutical innovation analysis (2018–2022).
- Legal Texts: China's Patent Law (latest amendments).
- Industry Reports: Chinese pharmaceutical patent trends and strategies.
This analysis aims to equip pharmaceutical professionals and legal representatives with detailed insights into CN101489560, supporting informed decision-making within China’s dynamic IP environment.
